Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Guiying Bai"'
Publikováno v:
Cancer Innovation, Vol 2, Iss 5, Pp 376-390 (2023)
Abstract Background Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype; most cases are triple‐negative breast cancers (TNBCs) and are poorly responsive to conventional systemic therapy. Few potential diagnostic and prognostic marker
Externí odkaz:
https://doaj.org/article/98519e4c2703438095e258e497e3c8f8
Autor:
Xu Wang MM, Yehui Shi MD, Yongsheng Jia MD, Weipeng Zhao MD, Li Zhang MD, Guiying Bai MM, Yulin Ren MM, Yong-Zi Chen PhD, Zhongsheng Tong MM
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Objective : This study aimed to investigate the tolerance and pharmacokinetic characteristics of recombinant human endostatin (rh-endostatin) administered as single-dose or multiple-dose infusions in patients with advanced solid tumors. Methods : Thi
Externí odkaz:
https://doaj.org/article/05d6a54ddabb4ee9a0628d134572ce97
Publikováno v:
International Journal of Genomics, Vol 2015 (2015)
This study has analyzed the gene expression patterns of an IPMN microarray dataset including normal pancreatic ductal tissue (NT), intraductal papillary mucinous adenoma (IPMA), intraductal papillary mucinous carcinoma (IPMC), and invasive ductal car
Externí odkaz:
https://doaj.org/article/fbe7dcdb37c84203a7b02931a97cc83b
Autor:
Liyan Zhou, Guiying Bai, Yue Song, Xiaohui Liu, Xiaoqing Li, Yilin Deng, Yiran Si, Yehui Shi, Hongli Li
Publikováno v:
Endocrine-Related Cancer; Sep2024, Vol. 31 Issue 9, p1-17, 17p
Publikováno v:
Journal of Clinical Oncology. 39:2044-2044
2044 Background: Management of advanced gliomas including glioblastoma multiforme (GBM) remains as an unmet medical need. Here we report our clinical experience with ACT001, or dimethylamino micheliolide, a synthesized derivative from parthenolide (a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9187d6f9f98b5a0d2d0cefbf7a90a9a5
https://doi.org/10.1200/jco.2021.39.15_suppl.2044
https://doi.org/10.1200/jco.2021.39.15_suppl.2044
Autor:
Yehui Shi, Aizong Shen, Guiying Bai, Yang Luo, Le Zhang, Yi Ba, Yan Wang, Xinghua Han, Lian Cao, Hui Zhou, Ting Deng, Yueyin Pan, Zhaoyi Yang
Publikováno v:
Journal of Clinical Oncology. 39:e15051-e15051
e15051 Background: Dysregulation of fibroblast growth factor receptor (FGFR) is strongly associated with establishment and progression of cancer. Pemigatinib is a selective FGFR1–3 inhibitor that are active in a targeted manner against cancers with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f78e7a0348884914c00acb402d9c83d
https://doi.org/10.1200/jco.2021.39.15_suppl.e15051
https://doi.org/10.1200/jco.2021.39.15_suppl.e15051
Autor:
Ming-Zhe Han, Lin Gui, Yuankai Shi, Jun Zhu, Dongmei Ji, Yuqin Song, Shiyu Jiang, Guiying Bai, Huilai Zhang, Weina Shen, Junning Cao, Qian Fan
Publikováno v:
Blood. 134:2840-2840
Background: CHOP is widely used for untreated PTCL patients (pts), although it has limited efficacy. Chidamide is an oral benzamide class of HDAC inhibitor with subtype specificity in inhibition of HDAC 1, 2, 3 and 10, approved in China for relapsed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0bfc18c66d5a19f16fa2c92dd7ade43
https://doi.org/10.1182/blood-2019-128078
https://doi.org/10.1182/blood-2019-128078